What the FDA's New Framework Means for Regenerative Therapies

The FDA recently passed a new policy framework governing the development and oversight of regenerative medicine. Attorney Michael Werner discussed these new policies and what they mean for the industry at large on an episode of RARECast.

Duration: 27:20